Mylab twice scanner

Manufactured by Esaote

Sourced in Italy

The MyLab Twice is a compact, portable ultrasound scanner developed by Esaote. It is designed for general diagnostic imaging applications.

Automatically generated - may contain errors

Lab products found in correlation

Sonovue, by Bracco (2 mentions) Mylab 70 xvg, by Esaote (1 mentions) Acuson s2000 scanner, by Siemens (1 mentions) Iu22 scanner, by Philips (1 mentions)

3 protocols using mylab twice scanner

Contrast-Enhanced Ultrasound for Liver Lesions

Check if the same lab product or an alternative is used in the 5 most similar protocols

CEUS was always preceded by a careful US survey, assessing the size and appearance of the lesion. This baseline assessment was done to appropriately choose the liver area or areas to be particularly focused in the forth- coming contrast-enhanced part of the US study. In all cases, a separated injection was performed for each liver lobe. For both injections, the arterial phase assessment was focused on any known lesion at baseline US. CEUS was performed as a low-mechanical index, double-split mode, real-time modality. We employed a Technos MyLab 70 XVG and MyLab Twice scanner (Esaote, Genoa, Italy), injecting 2.4 ml of a sulfur hexafluoride-based contrast medium (SonoVue, Bracco, Milan, Italy) per each liver lobe. After the injection, the radiologist focused the sonographic field of view on the parenchymal area of interest, waiting for the microbubbles arrival. Thereafter, he/she moved the transducer to explore the remaining parenchyma of each lobe, with special reference to the segment bearing the ablated lesion.

Granata V., Fusco R., Catalano O., Avallone A., Palaia R., Botti G., Tatangelo F., Granata F., Cascella M., Izzo F, & Petrillo A. (2017). Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. PLoS ONE, 12(6), e0179951.

+ Open protocol

+ Expand

Contrast-Enhanced Ultrasound (CEUS) for Liver Lesion Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols

CEUS was always preceded by a careful US survey, assessing the size and appearance of the lesion/s. This baseline assessment was done to appropriately choose the liver area or areas to be particularly focused in the forthcoming contrast-enhanced part of the US study. In all cases, a separated injection was performed for each liver lobe. For both injections, the arterial phase assessment was focused on any known lesion at baseline US. CEUS was performed as a low- mechanical index, double-split mode, real-time modality. We employed a Technos MyLab 70 XVG and MyLab Twice scanner (Esaote, Genoa, Italy), injecting 2.4 ml of a sulfur hexafluoride-based contrast medium (SonoVue, Bracco, Milan, Italy) per each liver lobe. After the injection, the radiologist focused the sonographic field of view on the parenchymal area of interest, waiting for the microbubble’s arrival. Thereafter, he/she moved the transducer to explore the remaining parenchyma of each lobe, with special reference to the resected area.

Patrone R., Granata V., Belli A., Palaia R., Albino V., Piccirillo M., Fusco R., Tatangelo F., Nasti G., Avallone A, & Izzo F. (2021). The safety and efficacy of Glubran 2 as biliostatic agent in liver resection. Infectious Agents and Cancer, 16, 19.

+ Open protocol

+ Expand

Ultrasound Evaluation of Breast Lesions

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients were examined with a MyLab Twice scanner (Esaote SpA, Genoa, Italy) using a 5–13‐MHz LA523 transducer, A LOGIQ E9 scanner (GE Healthcare, Chicago, IL) using 6–13‐MHz linear transducer, an iU22 scanner (Philips Healthcare, Andover, MA) using a 5–12‐MHz L12‐5 transducer, and an Acuson S2000 scanner (Siemens Medical Solutions, Mountain View, CA) using a 5.5–18‐MHz 18 L6 HD transducer. All images were collected by an image archiving and communication system and interpreted by 2 breast radiology experts (10 years of experience) in an independent fashion. Any discrepancy was resolved by consensus.
Each lesion was assigned a category (4A, 4B, 4C, or 5) according to the second edition of the American College of Radiology Breast Imaging Reporting and Data System for US.28 An ALN was believed to be positive for suspicious metastasis when it had one of the following characteristics: irregular cortical thickness of greater than 3 mm, longest‐to‐shortest axis ratio of less than 2, or absence of a fatty hilum.29

Qiu X., Jiang Y., Zhao Q., Yan C., Huang M, & Jiang T. (2020). Could Ultrasound‐Based Radiomics Noninvasively Predict Axillary Lymph Node Metastasis in Breast Cancer?. Journal of Ultrasound in Medicine, 39(10), 1897-1905.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!